Fierce Pharma
NOVEMBER 25, 2024
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the New York Yankees rallying to win the World Series as they trailed the Los | The FDA has signed off on BridgeBio's Attruby (acoramidis), a potential blockbuster to treat patients with the rare heart disease transthyretin amyloid cardiomyopathy.
MedCity News
NOVEMBER 25, 2024
A single source for provider credentialing would involve creating a centralized, continuously updated database of credentialing information that could be accessed and trusted across the healthcare sector. While no such system exists today, it should be the goal, and here’s why. The post The Case for a “Single Source of Truth” in Provider Credentialing appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 25, 2024
Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition. | In the phase 3 ZENITH study, Merck’s activin signaling inhibitor Winrevair met its primary endpoint of time to first morbidity or mortality event, which included all-cause death, lung transplantation, or hospitalization for at least 24 hours linked to disease worsening in patients with PAH.
MedCity News
NOVEMBER 25, 2024
Updated schema requirements are easy to mix up — here are a few simple solutions The post Common MRF Mistakes Hospitals Are Making in 2024 appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
NOVEMBER 25, 2024
Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol Myers Squibb's Revlimid and Roche's Rituxan—triggered a 57% reduction in the risk of disease progression, relapse or death in R/R FL patients compared with those who were treated with placebo, Revlimid and Rituxan.
MedCity News
NOVEMBER 25, 2024
Endoscopy, the standard for detecting esophageal precancer, is quite an invasive procedure — so a lot of people who should be screened end up never being tested. Lucid Diagnostics is trying to solve this problem by selling a quick, office-based diagnostic. The post This Pill-Size Diagnostic Seeks to Prevent Thousands of Esophageal Cancer Deaths appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 25, 2024
BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March. The post FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug appeared first on MedCity News.
Fierce Pharma
NOVEMBER 25, 2024
After a recent failed showing in a breast cancer subgroup raised doubts around AstraZeneca’s Truqap, the first-in-class AKT inhibitor is making inroads in a prostate cancer subtype. | The AKT inhibitor's early win in a prostate cancer subtype follows a recent surprise flop in a breast cancer study. AZ has been working to grow Truqap beyond its current limited approval in a niche breast cancer category.
MedCity News
NOVEMBER 25, 2024
Cortica’s $80 million raise was co-led by Morgan Health and Nexus NeuroTech Ventures and included participation from Autism Impact Fund. The post Cortica Snags $80M to Make Autism Care for Children Less Fragmented appeared first on MedCity News.
PharmaVoice
NOVEMBER 25, 2024
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the pandemic, although he describes himself as pro-vaccine.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
NOVEMBER 25, 2024
IT industry group techUK has called on the government to guarantee funding for digital transformation and cyber resilience in health and social care.
Clarify Health
NOVEMBER 25, 2024
The expectation to increase revenue and maintain sustainable profit margins is a constant drum for most health systems. Balancing the need for sustainable margins with the challenges of navigating complex payer contracts and regulatory demands is no easy feat. As health systems grapple with increasing pressure from payers, challenges in collecting and analyzing payer-negotiated rate data, and limited benchmarking capabilities, price transparency data emerges as a crucial tool for driving infor
pharmaphorum
NOVEMBER 25, 2024
After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer.
Pharmaceutical Commerce
NOVEMBER 25, 2024
In the second part of this roundtable discussion, key opinion leaders discuss the potential technological challenges surrounding RFID, and the likelihood of not only utilizing this tech at the item level but for product security purposes as well.
pharmaphorum
NOVEMBER 25, 2024
Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been unwilling to engage with negotiations.
European Pharmaceutical Review
NOVEMBER 25, 2024
The pharmaceutical analytical testing market is seeing significant growth following a greater incidence in the complexity of medicine development and higher demand for biologics and biosimilars, according to a report by Straits Research Pvt. Ltd. Their analysis projected that the market will exceed a value of $15.46 billion by 2032. The market is furthermore expected to see a compound annual growth rate (CAGR) of 7.3 percent between 2024 and 2032.
PharmExec
NOVEMBER 25, 2024
Pathway is now the first and only FDA-approved companion diagnostic for identifying HER2-positive biliary tract cancer patients eligible for treatment with Ziihera.
Pharmaceutical Technology
NOVEMBER 25, 2024
GSK has received approval from Japan's MHLW for its application to extend the indication of its RSV vaccine, Arexvy.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
NOVEMBER 25, 2024
BridgeBio grabs FDA approval for its ATTR cardiomyopathy drug Attruby, setting up a challenge to market leader Pfizer
PharmExec
NOVEMBER 25, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
NOVEMBER 25, 2024
The biopharmaceutical industry is being called to take its sustainability efforts to the next level. A new report sheds light on the topic.
PharmExec
NOVEMBER 25, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Pharmaceutical Technology
NOVEMBER 25, 2024
China’s NMPA has approved MSD’s WELIREG (belzutifan) to treat adult individuals with certain types of VHL disease-associated tumours.
PharmExec
NOVEMBER 25, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
NOVEMBER 25, 2024
The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
Pharmaceutical Commerce
NOVEMBER 25, 2024
The CDMO’s offerings will now feature automated fill-finish.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
NOVEMBER 25, 2024
Since 2023, the pharmaceutical industry operating in Europe has faced an unprecedented challenge related to drug shortages.
Pharmaceutical Commerce
NOVEMBER 25, 2024
The latest news for pharma industry insiders.
Pharmaceutical Technology
NOVEMBER 25, 2024
The US FDA has approved BridgeBio Pharma’s Attruby (acoramidis) for treating adult individuals with ATTR-CM.
Pharmacy Times
NOVEMBER 25, 2024
Findings highlight the unmet medical need for outpatient interventions and preventive measures that can reduce hospitalizations.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Expert insights. Personalized for you.
193 
Let's personalize your content